Glenmark Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹4,247 crore and net profit of ₹264 crore for the September 2026 quarter.
Glenmark Pharmaceuticals (NSE: GLENMARK) closed at ₹2,648.00 on 20 Nov 2026, up 41.0% over the past year. Its market capitalisation is ₹74,733 crore and it trades at 36.9 times earnings.
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.